Stragen
Damien Studer has a diverse work experience spanning over several years. Damien is currently working at Stragen as the Group Controller, where they oversee the Financial Planning and Analysis department. Prior to this, they worked as a Freelance FP&A - Financial Systems Consultant. Before that, Damien held the position of Head of Finance and Administration at the English National Programme - Non-Profit Organization. Additionally, they have worked at Edwards Lifesciences in various financial roles, including Finance Director, Global Critical Care, Head of Finance - Latin America, EU Heart Valves Therapy Controller, and EU Financial Planning & Analysis Manager. Damien also gained experience as a Financial Analyst at Sopra HR Software and Alstom Transport.
Damien Studer attended NEOMA Business School from 1999 to 2003. However, no specific degree or field of study is mentioned in the provided information. Prior to that, they attended Lycée International des Pontonniers - Strasbourg, but no start or end years are specified for this educational experience.
This person is not in any teams
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.